doxorubicin hydrochloride

P2, N=66, Not yet recruiting, Ou Bai, MD/PHD

Doxorubicin (DOX) was efficiently encapsulated via temperature-controlled loading to obtain DOX@FTn-EGFRAfb with high protein recovery, pH-responsive drug release, and strong stability...In an orthotopic U87 glioma mouse model, DOX@FTn-EGFRAfb significantly inhibited tumor growth and prolonged survival without obvious systemic toxicity. This work presents a versatile protein-engineering strategy for dual-targeted glioblastoma drug delivery.

P2, N=120, Not yet recruiting, BeBetter Med Inc

P1/2, N=12, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting

P2, N=40, Recruiting, French Innovative Leukemia Organisation | Trial completion date: Mar 2027 --> Sep 2029 | Trial primary completion date: Mar 2026 --> Mar 2028

Furthermore, these derivatives displayed higher selectivity for cancer cells over normal cells (SI > 44) compared to the positive controls, doxorubicin (SI > 2) and cisplatin (SI = 5). Molecular docking analysis indicated that these compounds (6a and 7b) form interactions with the aurora A kinase receptor both from structural and energetic perspectives. These results suggest that derivatives 6a and 7b have potential for further development as aurora A kinase inhibitors for colorectal cancer treatment.

P2, N=24, Recruiting, University of California, Davis | Trial primary completion date: Feb 2026 --> Oct 2026

P3, N=236, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Mar 2027 --> Mar 2026

Due to the diagnostic complexity, he was treated as having a non-Hodgkin lymphoma-like entity with R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) Although UCD is typically considered curable with surgical resection, this case demonstrates that, in rare cases, it can progress to lymphoma, specifically NLPHL. This case illustrates that even localized forms of UCD may be associated with subsequent lymphoid malignancy, emphasizing the importance of continuous clinical surveillance and a multidisciplinary approach to management. Histopathological reassessment of new lesions is crucial, and clinicians should consider the possibility of malignant transformation in patients with a history of UCD to ensure accurate diagnosis and timely treatment.

Here, we develop soft hybrid microparticles (3D-PMPs) by fusing tumor-repopulating cell-derived microparticles with inactivated platelet membranes to deliver the anticancer agent doxorubicin (DOX@3D-PMPs)...DOX@3D-PMPs demonstrate significantly enhanced therapeutic efficacy in both orthotopic 4T1 breast tumors and post-surgical orthotopic 4T1 breast tumors. This work offers a novel and effective approach to enhance the therapeutic outcomes in cancer treatment, particularly in post-surgical settings.

In Huh7 cells, it suppressed TAp63/Bax-mediated apoptosis while driving both oxidative phosphorylation and glycolysis, promoting resistance despite the absence of wild-type p53. These findings identify miR-203a-3p as a key modulator of DOX resistance in HCC through coordinated regulation of p53 family expression, apoptotic signaling, and metabolic rewiring, highlighting its potential as a therapeutic target for miRNA-based combination therapies.

In anti-diabetic assays, LREEs dose-dependently inhibited α-amylase and α-glucosidase, although less potent than acarbose. Cytotoxicity testing on HepG2 cancer cells showed an IC50 of 281.80 µg/mL, significantly higher than doxorubicin (34.07 µg/mL), indicating weak anticancer potential...The investigated material was evaluated as a mixed light rare earth oxide system to obtain an integrated biological response profile rather than to determine the contribution of individual oxide components. Therefore, the present findings represent system-level biological behaviour and serve as a foundation for more detailed component-specific investigations.